Evolva Holding SA (SIX: EVE), has completed the placing of all shares earmarked to satisfy certain liabilities and transaction expenses related to the Allylix acquisition, as announced on 16 December 2014. A total of 6.1 million shares were sold between 16 and 19 December. One Swiss investment fund acquired a block of five million shares. The transaction has no impact on the number of outstanding Evolva shares.
Jakob Dynnes Hansen, Evolva CFO, commented, “This placing went faster than we had expected and is a vote of confidence from the investment community.”
Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.
THIS PRESS RELEASE CONTAINS SPECIFIC FORWARD-LOOKING STATEMENTS, E.G. STATEMENTS INCLUDING TERMS LIKE BELIEVE, ASSUME, EXPECT OR SIMILAR EXPRESSIONS. SUCH FORWARD LOOKING STATEMENTS ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY RESULT IN A SUBSTANTIAL DIVERGENCE BETWEEN THE ACTUAL RESULTS, FINANCIAL SITUATION, DEVELOPMENT OR PERFORMANCE OF THE COMPANY AND THOSE EXPLICITLY OR IMPLICITLY PRESUMED IN THESE STATEMENTS. AGAINST THE BACKGROUND OF THESE UNCERTAINTIES READERS SHOULD NOT PLACE UNDUE RELIANCE ON FORWARD-LOOKING STATEMENTS OR TO ADAPT THEM TO FUTURE EVENTS OR DEVELOPMENTS.